# Emergent BioSolutions Inc. > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/Emergent BioSolutions Inc.). ## Overview Emergent BioSolutions Inc. is a U.S.-based life sciences company built around preparedness for public health threats, with products for opioid overdose, anthrax, smallpox and other emergency-response needs. It also operates a CDMO/Bioservices platform that provides development, manufacturing, fill-finish and packaging services to external biopharma, government and NGO customers. ## Products & services • NARCAN® Nasal Spray and KLOXXADO® naloxone products • Anthrax medical countermeasure products • Smallpox medical countermeasure products • Bioservices CDMO: development, drug substance and fill-finish • Packaging and suite reservation services • R&D contracts and grant-funded threat-response programs - **Commercial Products** (30%) — Naloxone products sold through retail, prescription and public-health channels. - **Anthrax MCM Products** (35%) — Anthrax countermeasure products procured mainly for government stockpiles and preparedness. - **Smallpox MCM Products** (15%) — Smallpox preparedness products sold under government procurement programs. - **Bioservices** (15%) — CDMO services including development, manufacturing, fill-finish and packaging for third parties. - **Other Products and R&D Funding** (5%) — Other legacy products, procured candidates and non-dilutive contract/grant funding. - NARCAN® Nasal Spray and KLOXXADO® naloxone products - Anthrax medical countermeasure products - Smallpox medical countermeasure products - Bioservices CDMO: development, drug substance and fill-finish - Packaging and suite reservation services - R&D contracts and grant-funded threat-response programs ## Customers The company sells to the U.S. government, foreign governments, and quasi-government/public-health organizations for stockpiling and emergency preparedness. It also serves retail pharmacies, health departments, law enforcement, community organizations and federal agencies for naloxone, plus biopharma companies and NGOs for CDMO services. Demand is driven by public-health readiness, procurement cycles, and the need for specialized manufacturing capacity. - **U.S. government procurement** (primary) — Buys anthrax, smallpox and other countermeasures for the Strategic National Stockpile and preparedness programs. - **Commercial naloxone channels** (primary) — Retail pharmacies, physician-directed prescriptions and public-health buyers purchase NARCAN and KLOXXADO to address opioid overdose emergencies. - **International government and quasi-government buyers** (secondary) — Foreign public-sector customers procure medical countermeasures for national preparedness and response needs. - **Biopharma and biotech CDMO customers** (secondary) — External developers buy development, drug substance, fill-finish and packaging services to move molecules toward commercialization. - **NGOs and public-health organizations** (emerging) — Purchase or fund bioservices and R&D work tied to infectious disease and emergency-response programs. - U.S. government agencies buying stockpile-ready countermeasures - Foreign governments procuring preparedness products - Retail pharmacies and prescription channels for naloxone - Health departments, law enforcement and community groups - Biopharma innovators needing development and manufacturing support - NGOs and government agencies funding or using bioservices ## Geography Emergent is headquartered in the United States and derives most of its business from U.S. government and U.S. commercial channels. Its services footprint includes development and manufacturing sites in the U.S. and Canada, and it also sells countermeasures to customers outside the U.S. Geography matters because procurement, regulatory approval and stockpile demand are highly country-specific, while manufacturing concentration creates operational exposure. - Headquartered in the United States - Largest customer is the U.S. government - Commercial naloxone sold mainly in U.S. retail and public-health channels - Development and manufacturing sites in the U.S. and Canada - International government sales add some non-U.S. exposure ## Strategy The company is focused on maintaining a portfolio of preparedness products while preserving its role as a supplier to government stockpiles and emergency-response channels. It is also using its integrated CDMO platform to support internal products and external customers, while prioritizing the most commercially and scientifically attractive programs. Portfolio discipline and manufacturing reliability are central to protecting contracts and credibility with public-sector buyers. - **Secure follow-on government procurement contracts** (short-term) — A large share of revenue depends on U.S. government stockpile and preparedness buying. - **Grow naloxone commercial penetration** (medium-term) — Commercial products diversify the business beyond government procurement cycles. - **Monetize bioservices capacity** (medium-term) — CDMO services can improve utilization of specialized manufacturing assets and broaden the customer base. - **Focus R&D on highest-value programs** (medium-term) — Capital is limited and the company has deprioritized some candidates, so portfolio selection is critical. - Defend and renew U.S. government procurement relationships - Support naloxone commercialization in retail and public-health channels - Use CDMO capabilities to monetize manufacturing infrastructure - Prioritize the most promising product candidates and programs - Maintain quality and compliance across manufacturing sites ## Risks The business is exposed to procurement concentration, especially dependence on U.S. government contracts and funding decisions. It also faces manufacturing, quality and compliance risk because its products and services rely on complex biologics operations, hazardous materials and specialized facilities. Competitive pressure, clinical uncertainty and contract renewal risk can all reduce revenue visibility and margins. - **U.S. government procurement concentration** [high] — The USG is the largest customer, so contract timing or funding changes can materially affect revenue. - **Contract renewal and funding risk** [high] — Existing procurement contracts may not be followed by new awards when they expire. - **Manufacturing quality and compliance** [high] — Biologics and countermeasure production requires strict controls; failures can trigger recalls, delays or lost contracts. - **Facility disruption** [high] — Unplanned outages at development or manufacturing sites can interrupt product supply and bioservices delivery. - **Clinical and development uncertainty** [medium] — Product candidates may fail to prove safe, effective or commercially viable. - Heavy dependence on U.S. government procurement and funding - Risk of not renewing follow-on countermeasure contracts - Manufacturing quality or compliance failures could disrupt supply - Facility outages or disruptions could halt products and bioservices - Clinical and regulatory uncertainty for product candidates - Competition from alternative countermeasures and biosimilar products ## Accounting Revenue can be volatile because deliveries, manufacturing services and government procurement timing are uneven across quarters. Investors should watch how the company recognizes fixed-price procurement contracts, CDMO services and grant-funded R&D, since timing differences can shift reported revenue between periods. Lease commitments, purchase obligations and impairment judgments also matter because the business relies on specialized facilities and has a portfolio of products and programs that can be reprioritized or divested. - **Revenue recognition timing** — Affects reported sales volatility and comparability - **Contract and grant accounting** — Affects revenue mix and gross margin - **Lease accounting** — Affects balance sheet liabilities and operating expense presentation - **Purchase commitments** — Affects liquidity and cost structure - **Impairment and divestiture accounting** — Affects reported earnings and asset base - Quarterly revenue can swing with delivery timing and manufacturing schedules - Government procurement contracts may create timing differences in revenue recognition - CDMO services and suite reservations can involve multi-step performance obligations - Grant and contract funding affects reported R&D revenue and margins - Lease and purchase commitments reflect specialized facility dependence - Impairment and divestiture accounting can affect asset values and gains/losses --- *Last updated: 2026-04-28T20:04:45.242073+00:00*